Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.49 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.49 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9220642 | 0.89 | GAA (0.59) | GAALGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL10622349 | 0.89 | GAA (0.59) | GAALGALS8LGALS3LGALS4L3MBTL1 | |
| SCHEMBL7545171 | 0.86 | AMY1A (0.55) | GAAL3MBTL1MAPTAMY1A | |
| SCHEMBL795680 | 0.86 | L3MBTL1 (0.50) | GAALGALS8LGALS3L3MBTL1MAPT | |
| SCHEMBL1096608 | 0.86 | AMY1A (0.55) | GAAL3MBTL1MAPTAMY1A | |
| SCHEMBL301721 | 0.86 | AMY1A (0.55) | GAAL3MBTL1MAPTAMY1A | |
| SCHEMBL17072438 | 0.86 | AMY1A (0.55) | GAAL3MBTL1MAPTAMY1A | |
| SCHEMBL2454313 | 0.86 | AMY1A (0.55) | GAAL3MBTL1MAPTAMY1A | |
| SCHEMBL17072443 | 0.86 | AMY1A (0.55) | GAAL3MBTL1MAPTAMY1A | |
| SCHEMBL9939094 | 0.86 | AMY1A (0.55) | GAAL3MBTL1MAPTAMY1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144879-A1 | FLUORESCENT PROBE FOR DETECTING CANCER | UNIV TOKYO (JP) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144879-A1 | FLUORESCENT PROBE FOR DETECTING CANCER | BRCA1, TP53, MKI67 | GAA 3649/4885LGALS8 859/4885LGALS3 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.